The acquisition unites two distinct scientific approaches to animal health. BiomEdit specializes in Programmable Veterinary Biologics™, which engineer beneficial bacteria to perform specific tasks, while Folium’s Guided Biotics® platform utilizes CRISPR-Cas technology to selectively target specific bacterial populations without disrupting the surrounding microbiome. According to BiomEdit CEO Aaron Schacht, this combination provides a broader toolkit to address complex production and health challenges in the animal sector.

Following the integration, BiomEdit will manage two advanced poultry programs. The company’s lead candidate, BE-101, remains in the final stages of conditional licensure with the USDA Center for Veterinary Biologics for the treatment of necrotic enteritis. Meanwhile, the newly acquired BiomElix® One offers an immediate commercial footprint in the Brazilian market. While financial details of the transaction remain undisclosed, the move consolidates a decade of research from the Folium team into BiomEdit’s existing infrastructure, which is backed by investors including Anterra Capital and Nutreco.